The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.

Of 15 treatment-emergent adverse events, only one was deemed related to therapy.

Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies. 

Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.

With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.

The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.